Njoku, Kelechi http://orcid.org/0000-0001-6528-3476
Pierce, Andrew http://orcid.org/0000-0001-5995-2469
Geary, Bethany
Campbell, Amy E.
Kelsall, Janet
Reed, Rachel
Armit, Alexander
Da Sylva, Rachel
Zhang, Liqun
Agnew, Heather
Baricevic-Jones, Ivona
Chiasserini, Davide http://orcid.org/0000-0002-1169-3258
Whetton, Anthony D.
Crosbie, Emma J. http://orcid.org/0000-0003-0284-8630
Funding for this research was provided by:
Cancer Research UK (C147/A25254)
RCUK | Medical Research Council (MR/M008959/1)
DH | National Institute for Health Research (NIHR300650)
Article History
Received: 27 July 2022
Revised: 17 December 2022
Accepted: 30 December 2022
First Online: 17 February 2023
Competing interests
: The authors declare no competing interests.
: Approval for this study was by the North-West Greater Manchester Research Ethics Committee (reference-16/NW/0660). All women gave written informed consent for their clinical data and urine samples to be used for research. The study was conducted in accordance with Good Clinical Practice guidelines and in line with the Helsinki declarations and the Human Tissue Act of 2004. All data obtained from study participants were handled and stored in compliance with the data protection principles of the General Data Protection Regulation (GDPR) 2018. We developed the research question in partnership with patients, carers and physicians in the James Lind Alliance (JLA) Detecting Cancer Early Priority Setting Partnership (Question#1: “What simple, non-invasive, painless, cost-effective, and convenient tests can be used to detect cancer early?”). The study also addresses the second most important research question of the JLA Womb Cancer Priority Setting Partnership (Question #2: “Which women with abnormal uterine bleeding should be referred for specialist review and which can be safely reassured?”).
: Not applicable.